Smith & Nephew SNATS SNN recently announced the receipt of FDA 510(k) clearance for its new CATALYSTEM Primary Hip System. The system is made to meet the changing needs of primary hip surgery, such as the growing popularity of anterior approach procedures and the growing significance of ambulatory surgery centers. Additionally, the CATALYSTEM Primary Hip System makes use of the exclusive, patent-pending ACCUBROACH Technology, which offers demonstrated reproducibility between the broach and implant, ensuring stem seating that is reliable and repeatable. More on the CATALYSTEM System To provide a precise fit, the CATALYSTEM Primary Hip System was created utilizing global data sets spanning femoral morphologies, building on the legacy of Smith & Nephew's clinically effective stem designs. With reduced distal stem geometry and shorter lengths, the system have a triple-taper stem design with homogeneous proximal loading that works well for anterior approaches but can also be used for other approaches. The design of CATALYSTEM facilitates accurate fit and fill proximally without distal interference. It is ideally suited for the direct anterior approach. Additionally, the system is delivered in a single modular tray, which helps drive efficiencies in facilitating more shelf space and reducing sterilization costs. Smith & Nephew's hip business has reached a significant milestone with the CATALYSTEM Primary Hip System, which enhances the company's current hip portfolio with a primary stem that is perfect for advanced anterior procedures, building on the excellent clinical record of POLAR3. The system is engineered for precision, confidence and surgical efficiencies, and the launch of the new stem combined with the company’s proprietary OXINIUM Technology and integration with its robotics platform will help Smith & Nephew continue to enhance patient outcomes in hip surgery. Industry Prospects Per a report by Precedence Research, the global hip replacement market size was estimated at $6.32 billion in 2023 and is expected to reach $10.7 billion by 2033 at a growth rate of 5.4%. An increase in the number of geriatric patients with osteoarthritis and other pain disorders, such as rheumatoid arthritis, is primarily associated with their increased participation in sports and increased risk of injury during play, which can result in fractures or ligament sprains and an increase in the number of patients requiring hospitalization. The market is growing steadily due to improved navigation for performing surgeries and greater robotic automation and networking. Notable Developments In June, SNN announced the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services. This launch is likely to provide personalized solutions for surgeons and patients across partial and total knee arthroplasty procedures. In April, SNN announced an exclusive distribution agreement with NAVBIT, a specialized player in surgical technology. This exclusive partnership, unveiled during the Australian Orthopedics Association COE Meeting in Sydney, marks a significant step in expanding its implant business in Australia. Price Performance For year-to-date period, SNN’s shares have gained 1.6% compared with the industry’s rise of 2.3%. The S&P 500 increased 17% in the same time frame. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Stocks to Consider SNN carries a Zacks Rank #4 (Sell) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are Elevance Health, Inc. ELV, Hologic HOLX and Universal Health Services UHS Elevance Health, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 12.2%. ELV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Elevance Health’s shares have rallied 22.1% compared with the industry’s 5.5% rise in the past year. Hologic, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 7.4%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 4.94%. Hologic’s shares have risen 0.3% year to date compared with the industry’s 4.7% growth. Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank of 2, at present. UHS has an estimated earnings growth rate of 30.5% for 2024. UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Universal Health Services, Inc. (UHS):Free Stock Analysis Report Smith & Nephew SNATS, Inc. (SNN):Free Stock Analysis Report Hologic, Inc. (HOLX):Free Stock Analysis Report Elevance Health, Inc. (ELV):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...